BPC-157
Also known as: Body Protection Compound 157 · BPC157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. Most-studied peptide in the recovery and tendon-healing community. Not approved for human medical use anywhere; sold as a research chemical.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like BPC-157, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any BPC-157 vendor.
Not medical advice. BPC-157 is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
BPC-157 was isolated from human gastric juice in the 1990s by Predrag Sikiric's lab in Zagreb. Animal studies show effects on angiogenesis (new blood vessel formation), tendon-to-bone healing, ligament repair, and gut barrier integrity. Proposed mechanisms include upregulation of growth hormone receptors in tendon fibroblasts, modulation of nitric oxide pathways, and influence on the dopaminergic system. Human trials are limited; what exists is mostly small Phase 1 and Phase 2 work for inflammatory bowel disease and one Phase 2 in knee pain. The bulk of the evidence base is rodent.
Typical practice
Community practice runs 250 to 500 mcg per day, subcutaneous, in 4 to 6 week cycles. Some users dose locally near the injury site (peri-injury) on the theory that systemic absorption is incomplete. Oral BPC-157 is sold but bioavailability is poorly characterised. Reconstitution is typically 5 mg vial in 2 to 5 mL bacteriostatic water. There is no established 'right dose' from human trials; everything in this paragraph reflects what users do, not what regulators have validated.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for BPC-157 in humans does not exist for most use cases listed.
Risks and contraindications
Most-reported side effects in user reports are mild: injection site reactions, occasional flushing, mild nausea. Theoretical risks worth knowing: BPC-157 promotes angiogenesis, which is precisely what tumours need to grow, so users with active or recent cancer should consult a real oncologist before any cycle. Cardiovascular safety in long-term use is uncharacterised. Drug interactions are not formally studied. Pregnancy and breastfeeding: avoid entirely. If you have IBD or any active inflammation, talk to a gastroenterologist first; don't self-treat.
Where this stands legally
FDA placed BPC-157 on the 503A bulks list under 'Category 2' in 2023, meaning compounding pharmacies cannot legally compound it for human use. Sold legally as a research chemical 'not for human consumption.'
Not a controlled substance. MHRA does not regulate research peptides; sale is technically lawful but human use is medically unsupervised and customs scrutiny on imports has tightened through 2025.
Not on EMA's approved list. Research peptide market is unregulated; cross-border imports occasionally seized. WADA prohibits BPC-157 in competitive sport (2024 list addition).
TGA Schedule 4 (prescription-only) since 2022. Personal-use imports of unscheduled peptides actively investigated. Don't import without a prescription.
Not formally scheduled. Sold by Bangkok wellness clinics and through research-peptide channels. Bộ Y Tế and FDA Thailand have not enforced against personal use as of 2026.
MOHAP treats peptides as prescription-only by default. Personal-use imports require a doctor's letter and may still be held at customs. Don't ship via courier.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Pure RawzPending Panya 11-signal audit
- Limitless LifePending Panya 11-signal audit
- Amino AsylumPending Panya 11-signal audit
- Rasa ResearchPending Panya 11-signal audit
- Bangkok-based research chem channelsPending Panya 11-signal audit
Full vendor scorecards for BPC-157 land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Sikiric et al. — Stable gastric pentadecapeptide BPC 157 in trials. Curr Pharm Des, 2018 →
- Chang et al. — Pentadecapeptide BPC 157 enhances tendon-to-bone healing. J Orthop Res, 2014 →
- Sikiric et al. — BPC 157 and standard angiogenic growth factors. Inflammopharmacology, 2018 →
- WADA 2024 Prohibited List (BPC-157 entry, S0 Non-Approved Substances) →
People asking adjacent questions
If you have a specific tendon or joint injury that has plateaued on conservative management and you accept that the human evidence is thin, then yes, on a defined 4 to 6 week cycle...
BPC-157 if your injury is tendon, ligament, or gut. TB-500 if it's soft tissue (muscle tear, joint capsule). Stacking both is the community default but the human evidence does not ...
Panya blog posts
Roughly 25 percent of weight lost on tirzepatide is lean mass unless you intervene. The protein target, training cadence, and supplement stack that preserves muscle during GLP-1 we...
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
Adjacent reading
Track BPC-157 in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.